Incyte Co. (NASDAQ:INCY) – Research analysts at Gabelli issued their FY2022 earnings estimates for shares of Incyte in a note issued to investors on Friday. Gabelli analyst J. He expects that the biopharmaceutical company will post earnings per share of $5.05 for the year.
Incyte (NASDAQ:INCY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.54. The firm had revenue of $444.20 million for the quarter, compared to analysts’ expectations of $435.23 million. Incyte had a negative return on equity of 11.85% and a negative net margin of 20.38%. The business’s quarterly revenue was up 36.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.05 EPS.
Several other research firms have also recently commented on INCY. BMO Capital Markets cut their target price on Incyte from $163.00 to $162.00 and set an “outperform” rating on the stock in a research note on Thursday, October 26th. JPMorgan Chase & Co. restated a “buy” rating on shares of Incyte in a research note on Wednesday, October 25th. Oppenheimer set a $135.00 target price on Incyte and gave the company a “hold” rating in a research note on Tuesday, October 31st. Zacks Investment Research cut Incyte from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Finally, Royal Bank of Canada cut their target price on Incyte from $136.00 to $120.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 21st. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $142.94.
Incyte (NASDAQ:INCY) traded down $0.80 during midday trading on Monday, reaching $84.71. The company’s stock had a trading volume of 1,365,458 shares, compared to its average volume of 1,859,431. The company has a market cap of $18,060.00, a PE ratio of -54.30 and a beta of 0.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.01 and a quick ratio of 3.99. Incyte has a 12-month low of $80.85 and a 12-month high of $153.15.
In related news, insider David W. Gryska sold 6,760 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $98.87, for a total transaction of $668,361.20. Following the transaction, the insider now directly owns 20,752 shares of the company’s stock, valued at approximately $2,051,750.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Vijay K. Iyengar sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $97.26, for a total value of $486,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 12,456 shares of company stock worth $1,222,876 over the last three months. 17.70% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of the stock. Sands Capital Management LLC boosted its stake in Incyte by 8.2% in the 4th quarter. Sands Capital Management LLC now owns 8,191,287 shares of the biopharmaceutical company’s stock valued at $775,797,000 after purchasing an additional 621,323 shares during the period. Capital International Investors boosted its stake in Incyte by 1.4% in the 3rd quarter. Capital International Investors now owns 6,494,566 shares of the biopharmaceutical company’s stock valued at $758,176,000 after purchasing an additional 87,369 shares during the period. Geode Capital Management LLC boosted its stake in Incyte by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 1,938,238 shares of the biopharmaceutical company’s stock valued at $183,205,000 after purchasing an additional 105,692 shares during the period. Bank of New York Mellon Corp boosted its stake in Incyte by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 1,682,019 shares of the biopharmaceutical company’s stock valued at $159,304,000 after purchasing an additional 7,463 shares during the period. Finally, Jennison Associates LLC boosted its stake in Incyte by 24.3% in the 3rd quarter. Jennison Associates LLC now owns 1,633,173 shares of the biopharmaceutical company’s stock valued at $190,657,000 after purchasing an additional 319,191 shares during the period. 89.43% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Gabelli Weighs in on Incyte Co.’s FY2022 Earnings (INCY)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/21/gabelli-weighs-in-on-incyte-co-s-fy2022-earnings-incy.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.